Tryp Therapeutics

Tryp Therapeutics

Private Company
Public Company
Subsidiary of
Clinical Trials, R&D
Drug Discovery


Tryp Therapeutics is a pharmaceutical company focused on developing compounds with known activity and/or safety profiles for the treatment of rare diseases and other diseases with high unmet medical needs. Tryp’s psilocybin-for-neuropsychiatric disorders, or PFN™️, program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of certain neuropsychiatric-based disorders. Tryp’s lead PFN™️ drug candidate is TRP-8802 for the treatment of fibromyalgia, a chronic pain syndrome estimated to affect more than 5 million people in the United States.  

In addition to its PFN™️ Program, Tryp is also developing TRP-1001, an oral formulation of razoxane for the treatment of soft tissue sarcoma.  Soft tissue sarcomas are a rare and diverse group of tumors that account for about 1% of all cancers in adults and 7% in children.  Based on the prevalence of soft tissue sarcomas in the United States, Tryp believes it is a rare disease and that TRP-1001 should qualify for Orphan Drug status.

Leadership Team

The TRYP Management team has decades of experience building successful pharmaceutical and biotech companies together, and bring a balanced combination of capital markets experience, Big Pharma and FDA expertise (having successfully brought drugs to market), and a track record of building profitable public companies. 



Greg McKee, CEO & Chairman

  • Extensive experience leading publicly traded pharmaceutical companies and brings a vast network of relationships in the life science industry.
  • Began his life science career at Genzyme where he was responsible for commercializing leading compounds for rare diseases throughout Asia.
  • Chairman and CEO of Nventa Biopharmaceuticals Corporation and Akela Pharma Inc., both publicly traded biopharmaceutical companies.
  • CEO of CONNECT, an early stage incubator, and as Managing Director at Torrent Ventures.
  • Was previously appointed as Chairman of the Board of Directors of Tryp in February 2021.

William Garner, Executive Chairman

  • Founder of Race Oncology (ASX:RAC)
  • Co-Founder and Director of DelMar Pharmaceuticals (NASDAQ:DMPI)
  • Founder of EGB Ventures, where he was focused on advancing technologies and companies to monetization or assets via licensing, mergers and acquisitions or IPO transactions.

Tom D’Orazio, Chief Operating Officer 

  • Formerly CEO, ImmunoPrecise Antibodies (TSXV:IPA).
  • Co-Founder & CEO of Superna Life Sciences 
  • Previous Big Pharma experience at Pfizer & QLT leading larger partnerships & product portfolios. 
  • MBA, Vanderbilt University & BSc in Chemistry from Loyola University, Chicago  

Dr. Jim Gilligan, President & Chief Science Officer

  • PhD from the University of Connecticut & MBA from Seton Hall University 
  • Over 35 years of experience in the life sciences industry, including R&D, clinical development, international regulatory affairs, and CMC manufacturing.
  • Co-Founder of Unigene Laboratories 
  • Co-Founder & Chief Science Office of Tarsa Therapeutics

James Kuo, Director

  • Chairman of the Board, ImmunoPrecise Antibodies (TSXV:IPA).
  • Former Managing Director of HealthCare Ventures, a $378 Million venture capital fund.
  • Former CEO of BioMicro Systems and Discovery Laboratories.
  • Former Associate Director of Licensing and Development at Pfizer.
  • MD from University of Pennsylvania School of Medicine.
  • MBA from the Wharton School of Business.

Pipeline / Market Opportunities

TRYP’s PFN™ Program

Tryp’s  PFN™ program is focused on developing orally-delivered drug therapies for certain neuropsychiatric disorders that have distinct advantages over other drugs that are currently in the market or are in development.  



TRP-8802 | Fibromyalgia

Chronic and debilitating CNS/neurobiological disorder. The fibromyalgia treatment market is estimated to surpass US$3.6B by 2026.

TRP-1001 | Razoxane (Soft Tissue Sarcomas)

Oncology is the leading therapeutic category and represented 25% of all drug sales in 2018, which equated to ~US$151B in 2018.